KLOW

KLOW-80 is a defined four-component blend, not a single peptide. Each vial contains GHK-Cu 50 mg, TB-500 10 mg, BPC-157 10 mg, and KPV 10 mg, for a total nominal content of 80 mg. KLOW-80 uses the same three-component base as GLOW-70 and adds KPV as a separate anti-inflammatory-pathway research variable.

• GHK-Cu (50 mg): a copper(II)-complexed tripeptide (glycyl-L-histidyl-L-lysine-Cu). Fibroblast studies have reported increased collagen synthesis. Other cell studies found changes in MMP-2 and its tissue inhibitors, linking GHK-Cu research to both extracellular-matrix production and matrix turnover.
• TB-500 (10 mg): a supplier-designated thymosin-beta-4-related research component. Native thymosin beta 4 binds monomeric actin and has been studied in cell migration, endothelial sprouting, cytoskeletal remodeling, and experimental wound models. Interpretation should remain lot-specific because the commercial name TB-500 alone does not establish structural equivalence to native thymosin beta 4.
• BPC-157 (10 mg): an experimental 15-amino-acid peptide. Endothelial-cell and animal studies have associated BPC-157 with VEGFR2 expression and internalization, followed by Akt-eNOS pathway activation and angiogenesis-related endpoints. This evidence is preclinical.
• KPV (10 mg): Lys-Pro-Val, the C-terminal tripeptide of alpha-melanocyte-stimulating hormone. Cell studies found PepT1-mediated uptake with reduced NF-kappaB and MAP-kinase activation and lower pro-inflammatory cytokine output. Anti-inflammatory findings have also been reported in mouse colitis models; these results do not establish the behavior of KPV in this injectable multi-peptide blend.

These mechanisms describe research on the individual components or closely related materials. No direct published study was identified for this exact 50:10:10:10 co-lyophilized formulation. Synergy, potency, stability, and biological response must therefore be measured for the blend itself and must not be inferred by simply adding the reported effects of the separate components.

This product is supplied as a lyophilized powder. Unopened vials can be stored at room temperature for up to 2 years when kept sealed, dry, and protected from light. Avoid excessive heat, moisture, and repeated temperature changes during storage.

After reconstitution, store the solution at 2-8°C, protected from light, and use it within 30 days. Label the vial with the reconstitution date. Use sterile handling, avoid vigorous shaking and repeated freeze-thaw cycles, and do not use the material if the seal is damaged or if persistent particles, unexpected cloudiness, or discoloration is present after dissolution.

For concentration calculations after adding V mL of solvent, the nominal component concentrations are GHK-Cu 50/V mg/mL, TB-500 10/V mg/mL, BPC-157 10/V mg/mL, and KPV 10/V mg/mL. The total nominal blend concentration is 80/V mg/mL. Reconstitution volume changes concentration but does not change the fixed 5:1:1:1 mass ratio. Use the lot-specific COA and an appropriate analytical method when measured concentration or identity is required.